---
title: "Key facts: NMRA Halts Navacaprant; 35% cut, Runway Q3 2027; 511/898/215"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289878539.md"
description: "Neumora Therapeutics (NMRA) halted development of antidepressant navacaprant after two late-stage trials failed to meet primary endpoints in major depressive disorder patients. 1Neumora Therapeutics (NMRA) cut ~35% staff to save about $10M annually, extending cash runway into Q3 2027; refocusing on NMRA-511, NMRA-898 and NMRA-215 with upcoming data and starts. 2 3Neumora (NMRA) pipeline updates: NMRA-511 MAD cohort in elderly completes Q4 2026 to guide Phase 2b by year-end; NMRA-898 Phase 1 data due H2 2026; NMRA-215 toxicology mid-2026, trials by year-end. 4"
datetime: "2026-06-16T07:13:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289878539.md)
  - [en](https://longbridge.com/en/news/289878539.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289878539.md)
---

# Key facts: NMRA Halts Navacaprant; 35% cut, Runway Q3 2027; 511/898/215

-   Neumora Therapeutics (NMRA) halted development of antidepressant navacaprant after two late-stage trials failed to meet primary endpoints in major depressive disorder patients. 1
-   Neumora Therapeutics (NMRA) cut ~35% staff to save about $10M annually, extending cash runway into Q3 2027; refocusing on NMRA-511, NMRA-898 and NMRA-215 with upcoming data and starts. 2 3
-   Neumora (NMRA) pipeline updates: NMRA-511 MAD cohort in elderly completes Q4 2026 to guide Phase 2b by year-end; NMRA-898 Phase 1 data due H2 2026; NMRA-215 toxicology mid-2026, trials by year-end. 4

### Related Stocks

- [NMRA.US](https://longbridge.com/en/quote/NMRA.US.md)

## Related News & Research

- [Penny Stock Neumora Therapeutics Cuts Workforce After Depression Trials Fail](https://longbridge.com/en/news/289813061.md)
- [Neumora Therapeutics scraps depression drug after two late-stage trial failures](https://longbridge.com/en/news/289781036.md)
- [Mira Pharmaceuticals submits FDA Phase 2a trial protocol for Ketamir-2 in chemotherapy-induced neuropathy](https://longbridge.com/en/news/290049499.md)
- [Spyre says bowel disease drug cuts inflammation in mid-stage trial](https://longbridge.com/en/news/289783190.md)
- [cAMPfield Therapeutics raises $180 million Series A led by Frazier, backed by Forbion](https://longbridge.com/en/news/290194751.md)